Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.54 |
| ▸ | GABRD | O14764 | 1/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.54 |
| ▸ | GABRE | P78334 | 1/20 | 0.54 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.54 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.54 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.54 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | RORC | P51449 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30192167 | 1.00 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28731102 | 0.89 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16922170 | 0.89 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL28928381 | 0.87 | GABRP (0.69) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11880121 | 0.86 | SMN1; SMN2 (0.50) | MAPK1RORCMAPTKMT2AMEN1 | |
| SCHEMBL11826307 | 0.85 | RORC (0.56) | MAPK1RORCMAPTKMT2AMEN1 | |
| SCHEMBL31541287 | 0.84 | MEN1 (0.52) | MAPK1MAPTKMT2AMEN1LMNA | |
| SCHEMBL30192101 | 0.83 | RORC (0.49) | MAPK1RORCMAPTKMT2AMEN1 | |
| SCHEMBL10813064 | 0.83 | GABRP (0.76) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8635787 | 0.81 | GABRP (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115557906-A | Preparation method of clonazepam | 华中药业股份有限公司 | 2023-01-03 | — | — | CN | disclosed |
| EP-0768895-B1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEV CORP (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20020016293-A1 | Flavopiridol drug combinations and methods with reduced side effects | NIH - DEITR | 2002-02-07 | — | — | US | disclosed |
| WO-2001080896-A2 | FLAVOPIRIDOL DRUG COMBINATIONS AND METHODS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
| US-5786344-A | ADMINISTERING WITH AGENT WHICH INCREASES ACTIVITY OF GLUCURONOSYLTRANSFERASE OR DECREASES ACTIVITY OF BILIARY TRANSPORT PROTEIN | ARCH DEVELOPMENT CORPORATION (US) | 1998-07-28 | — | — | US | disclosed |
| EP-0768895-A1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001127-A1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 1996-01-18 | — | — | WO | disclosed |
| US-3996209-A | Process for preparing benzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016293-A1 | Flavopiridol drug combinations and methods with reduced side effects | UGT1A1, UGT1A3, CYP7A1 | GABRP 1741/4885GABRD 1835/4885GABRA1 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.